MXPA06004647A - Sal antagonista de ccr-2. - Google Patents

Sal antagonista de ccr-2.

Info

Publication number
MXPA06004647A
MXPA06004647A MXPA06004647A MXPA06004647A MXPA06004647A MX PA06004647 A MXPA06004647 A MX PA06004647A MX PA06004647 A MXPA06004647 A MX PA06004647A MX PA06004647 A MXPA06004647 A MX PA06004647A MX PA06004647 A MXPA06004647 A MX PA06004647A
Authority
MX
Mexico
Prior art keywords
added
trifluoromethyl
solution
pyran
compound
Prior art date
Application number
MXPA06004647A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Richard Sidler
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MXPA06004647A publication Critical patent/MXPA06004647A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA06004647A 2003-10-27 2004-10-25 Sal antagonista de ccr-2. MXPA06004647A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27
PCT/US2004/035069 WO2005044264A1 (en) 2003-10-27 2004-10-25 Ccr-2 antagonist salt

Publications (1)

Publication Number Publication Date
MXPA06004647A true MXPA06004647A (es) 2006-06-27

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06004647A MXPA06004647A (es) 2003-10-27 2004-10-25 Sal antagonista de ccr-2.

Country Status (21)

Country Link
US (1) US7473696B2 (ja)
EP (1) EP1682135B1 (ja)
JP (1) JP4542550B2 (ja)
KR (1) KR20060101476A (ja)
CN (1) CN1870998B (ja)
AT (1) ATE517622T1 (ja)
AU (1) AU2004287416C1 (ja)
BR (1) BRPI0415836A (ja)
CA (1) CA2543201C (ja)
CO (1) CO5690606A2 (ja)
EC (1) ECSP066524A (ja)
IL (1) IL175009A0 (ja)
IS (1) IS8400A (ja)
MA (1) MA28104A1 (ja)
MX (1) MXPA06004647A (ja)
NO (1) NO20062377L (ja)
NZ (1) NZ546447A (ja)
RU (1) RU2317295C1 (ja)
UA (1) UA81365C2 (ja)
WO (1) WO2005044264A1 (ja)
ZA (1) ZA200602752B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262077B (en) 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
ATE555087T1 (de) 2002-11-27 2012-05-15 Incyte Corp 3-aminopyrrolidinderivate als modulatoren von chemokinrezeptoren
EP1606280A4 (en) * 2003-03-18 2008-12-24 Merck & Co Inc CYCLOPENTYL HETEROCYLIC TETRAHYDROPYRANYL AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
US7576089B2 (en) 2003-12-18 2009-08-18 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
JP2007537264A (ja) 2004-05-11 2007-12-20 インサイト コーポレイション ケモカインレセプタのモジュレータとしての3−(4−ヘテロアリールシクロヘキシルアミノ)シクロペンタンカルボキサミド
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
BRPI0512634A (pt) 2004-06-28 2008-03-25 Incyte Corp 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
KR100856156B1 (ko) 2004-06-28 2008-09-03 인사이트 코포레이션 케모카인 수용체의 조절자로서의3-아미노사이클로펜탄카복스아마이드
JP2010510224A (ja) 2006-11-17 2010-04-02 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのアミノピロリジン類
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
WO2014133072A1 (ja) 2013-02-28 2014-09-04 参天製薬株式会社 テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤
CN108135168B (zh) 2015-05-21 2021-07-20 凯莫森特里克斯股份有限公司 Ccr2调节剂
MX2020003192A (es) 2017-09-25 2020-07-29 Chemocentryx Inc Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1.
JP7442141B2 (ja) 2018-01-08 2024-03-04 ケモセントリックス,インコーポレイティド Ccr2アンタゴニストによる固形腫瘍の治療方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
FR2787790A3 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1°2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl!-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
US6500844B1 (en) * 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
EP1318811B1 (en) * 2000-08-17 2006-08-30 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
EE200300247A (et) * 2000-11-28 2003-10-15 Pfizer Products Inc. Isotiasool-4-karboksamiidi soolad ja nende kasutamine hüperproliferatsioonivastaste vahenditena
KR20040066140A (ko) * 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
DK1501507T3 (da) * 2002-04-29 2008-09-29 Merck & Co Inc Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
TWI262077B (en) * 2002-04-29 2006-09-21 Merck & Co Inc Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JP4459807B2 (ja) * 2002-04-29 2010-04-28 メルク エンド カムパニー インコーポレーテッド テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
EP1682135A1 (en) 2006-07-26
CN1870998A (zh) 2006-11-29
RU2317295C1 (ru) 2008-02-20
CA2543201C (en) 2010-12-21
EP1682135B1 (en) 2011-07-27
AU2004287416A1 (en) 2005-05-19
ATE517622T1 (de) 2011-08-15
EP1682135A4 (en) 2009-11-25
CO5690606A2 (es) 2006-10-31
IS8400A (is) 2006-04-06
JP4542550B2 (ja) 2010-09-15
AU2004287416B2 (en) 2009-11-19
ECSP066524A (es) 2006-10-10
MA28104A1 (fr) 2006-08-01
US7473696B2 (en) 2009-01-06
US20070135474A1 (en) 2007-06-14
WO2005044264A1 (en) 2005-05-19
KR20060101476A (ko) 2006-09-25
BRPI0415836A (pt) 2007-01-02
ZA200602752B (en) 2007-08-29
AU2004287416C1 (en) 2010-09-09
CN1870998B (zh) 2010-10-20
IL175009A0 (en) 2006-08-20
JP2007509940A (ja) 2007-04-19
NO20062377L (no) 2006-05-24
UA81365C2 (en) 2007-12-25
NZ546447A (en) 2009-02-28
CA2543201A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
MXPA06004647A (es) Sal antagonista de ccr-2.
US7153967B2 (en) Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates
US6635630B2 (en) Selective neurokinin antagonists
AU2012335039C1 (en) 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US7361765B2 (en) Process for the preparation of CCR-2 antagonists
SI9300286A (sl) Ciklopentan- in -penten-beta-amino kisline
AU2011336217B2 (en) KAT II inhibitors
US7232907B2 (en) Process for production of naphthyridine-3-carboxylic acid derivatives
US6803467B2 (en) Intermediates for the production of quinolone carboxylic acid derivatives
MXPA06005550A (es) Agentes antibacterianos.
US6770763B2 (en) Asymmetric synthesis of amino-pyrrolidinones
US11254679B2 (en) Process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrroldin-1-yl)cyclohexyl)acetamide
IL112323A (en) Process and intermediates for the preparation of salts of acid 7 - (1a, 5b, 6a) - (6 - amino - 3 azabicyclo [0.1.3] - hex - 3yl) - 1 - (2, 4 - difluorophenyl) - 6 - fluorine - 4,1 - Dihydro - 4 - Oxo - 1,8 - Naphthiridine - 3 - Carboxylate
KR20110104933A (ko) 피페리딘 유도체의 입체선택적 합성
BG64094B1 (bg) Метод за получаване на нафтиридони и междинни съединения

Legal Events

Date Code Title Description
FG Grant or registration